The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies
The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies
Recruiting · NCT07002112 · Registry updated 2026-05-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence | Recruiting | Phase 1 | 2026-05-14 | NCT07002112 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Nanjing Legend Biotech Co. | 13 |
| The First Affiliated Hospital with Nanjing Medical University | 319 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Gobroad Boren Hospita | Beijing | China | 1 |
| The First Affiliated Hospital of USTC west district | Hefei | China | 1 |
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou | China | 56 |
| The First Affiliated Hospital with Nanjing Medical University | Nanjing | China | 32 |
| the Fourth Hospital of Hebei Medical University | Shijiazhuang | China | 19 |
| Union Hospital Tongji Medical College Huazhong University of Science and Technology | Wuhan | China | 12 |